Occam Places CMO at Xenotransplantation Biotech
In May 2025, Occam Global recruited Jay Barth, MD as CMO of eGenesis.
Dr. Barth is a serial biotech CMO with rich experience shepherding the clinical progress of novel modalities across diverse disease states. He joins eGenesis from Ascidian Therapeutics, where he led the company's RNA Exon Editing technology into the clinic. His prior roles include that of CMO for orphan disease pioneer Amicus Therapeutics and SVP of Clinical Development at PTC Therapeutics, where he led a landmark approval for Duchenne Muscular Dystrophy.
Barth earned his B.A. from Columbia University and M.D. from the University of Pennsylvania School of Medicine.
About eGenesis
eGenesis is a George Church company pioneering a genome engineering-based approach to develop safe, effective transplantable organs to end the global organ shortage. In the last year, the company has successfully completed two porcine - human kidney transplants and is using funds from a recently closed $191M Series D round to progress programs in the heart, liver and kidney to the clinic. Investors include Lux Capital, ARCH Ventures, Khosla Ventures, Farallon Capital Management, Leaps by Bayer, Polaris Partners, Catalio Capital Management, and Osage University Partners.
Related Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.